Výsledky vyhledávání - "Gilmour Morrison"

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

Autor: Gilmour Morrison, Kevan E. VanLandingham, David Critchley, Jerzy P. Szaflarski, Barry E. Gidal, Philip N. Patsalos

Publikováno v: Epilepsia

Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety profile in patients with Lennox‐Gastaut syndrome or Dravet syndrome in randomized, double‐blind, add‐on, controlled phase 3 trials. It is important to conside

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::295bacc3f5c92b68b43ab9167d357758
https://doi.org/10.1111/epi.16674

Zobrazit plný text záznamu

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam

Autor: Lesley Taylor, Kevan E. VanLandingham, Gilmour Morrison, Julie Crockett

Publikováno v: Journal of Clinical Pharmacology

We investigated the effects of cannabidiol (CBD; 21‐day maintenance dose) on the pharmacokinetics (PK) of clobazam (CLB) and monitored the safety of CBD (or placebo) plus CLB in 20 patients with uncontrolled epilepsy on stable doses of CLB. Blood s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eb7cfc1c92b0a2fe56d07336c385aa3
https://doi.org/10.1002/jcph.1634

Zobrazit plný text záznamu

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

Autor: Gilmour Morrison, Carmen María Arenas Cabrera, Boudewijn Gunning, David Critchley, Julie Crockett, Manuel Toledo, Louise Wray, Kevan VanLandingham, Bola Tayo, Elinor Ben-Menachem

Publikováno v: CNS Drugs

Background In recent randomized, placebo-controlled, phase III trials, highly purified cannabidiol demonstrated efficacy with an acceptable safety profile in patients with Lennox–Gastaut syndrome or Dravet syndrome. It is anticipated that antiepile

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32cab96f30b48559f58e5b435191b8c
http://europepmc.org/articles/PMC7275018

Zobrazit plný text záznamu

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

Autor: Farhad Sahebkar, Lesley Taylor, Bola Tayo, Gilmour Morrison

Publikováno v: Clinical Pharmacokinetics

Introduction As patients who receive cannabidiol (CBD) may have co-existing renal morbidities, it is important to understand whether dose adjustments are necessary to mitigate the risk of exposure-related toxicity. This study was conducted to evaluat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a22beca23efd0b1631b0bacb18ff6fd5
https://doi.org/10.1007/s40262-019-00841-6

Zobrazit plný text záznamu

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

Autor: Gilmour Morrison, Bola Tayo, Julie Crockett, Lesley Taylor

Publikováno v: Journal of Clinical Pharmacology

The pharmacokinetics and safety of a single oral dose of 200‐mg plant‐derived pharmaceutical formulation of highly purified cannabidiol (CBD) in oral solution (Epidiolex in the United States; 100 mg/mL) were assessed in subjects with mild to seve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b06dd9f92078e4f8e36ba793dbc62c46
https://doi.org/10.1002/jcph.1412

Zobrazit plný text záznamu

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

Autor: Graham Blakey, Kenneth W. Sommerville, Gilmour Morrison, Julie Crockett

Publikováno v: Clinical Pharmacology in Drug Development

GW Pharmaceuticals’ formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox‐Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valpr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c1329fd5235563e8075f3490449ce68
https://doi.org/10.1002/cpdd.665

Zobrazit plný text záznamu

Plný text ve formátu HTML

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

Autor: Barry E. Gidal, Gilmour Morrison, Bola Tayo, Graham Blakey, Lesley Taylor

Publikováno v: CNS Drugs

Background A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and to examine the effect of food on CBD PK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23f40babbda7d0ca068965b111b82f59
https://doi.org/10.1007/s40263-018-0578-5

Zobrazit plný text záznamu

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

Autor: Matthew Wong, Sam M. Greenwood, Orrin Devinsky, Anup D. Patel, Kenneth Sommerville, Richard Appleton, Gilmour Morrison, Cynthia L. Harden, Elizabeth A. Thiele

Publikováno v: Neurology
Wong, M H 2018, ' Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome ', Neurology, vol. 90, no. 14, pp. e1204-e1211 . https://doi.org/10.1212/WNL.0000000000005254

ObjectiveTo evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome.MethodsPatients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::314f07608b4cb059dde2c6910b87ee19
http://europepmc.org/articles/PMC5890607

Zobrazit plný text záznamu

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects

Autor: Bola Tayo, David Critchley, Joris Berwaerts, Gilmour Morrison, Julie Crockett

Publikováno v: Epilepsia

Objective The pharmacokinetics (PK) and safety of single oral 750‐mg doses of a plant‐derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the USA and Epidyolex in Europe; 100‐mg/mL oral solution) were assessed i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cf6bba875e195d7b1bb9fd20b56d44f
https://pubmed.ncbi.nlm.nih.gov/32012251

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání